Biofrontera AG (0DOL.L)

Name: Biofrontera AG Financial Statements
Creator: Quarter Results

Healthcare | Medical Pharmaceuticals

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$17.1M

Net Income

$5.6M

Operating Margin

26.7%

Free Cash Flow

-$13.4M

Debt / Assets

63.3%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Biofrontera AG (0DOL.L).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Revenue	17,100,000	6,988,000	9,030,000	8,588,000
Cost of Revenue	2,734,000	1,922,000	2,380,000	3,075,000
Gross Profit	14,366,000	5,066,000	6,650,000	5,513,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	8,523,000	10,047,000	10,528,000	8,653,000
Operating Expenses	9,808,000	11,344,000	11,729,000	10,060,000
Operating Income	4,558,000	-6,278,000	-5,079,000	-4,547,000
Interest Expense	120,000	111,000	115,000	120,000
Income Before Tax	5,640,000	-6,643,000	-5,303,000	-4,204,000
Income Tax Expense	-1,000	6,000	21,000	-1,000
Net Income	5,640,000	-6,649,000	-5,324,000	-4,203,000
Per Share
EPS	0.48	-0.62	-0.57	-0.76
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Biofrontera AG (0DOL.L).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue	41,705,000	37,303,000	34,071,000	25,738,000
Cost of Revenue	10,111,000	18,607,000	17,444,000	4,756,000
Gross Profit	31,594,000	18,696,000	16,627,000	20,982,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	37,751,000	33,835,000	39,127,000	12,263,000
Operating Expenses	42,942,000	35,924,000	39,304,000	64,030,000
Operating Income	-11,348,000	-17,210,000	-22,677,000	1,591,000
Interest Expense	452,000	2,106,000	600,000	0
Income Before Tax	-10,511,000	-17,737,000	-20,117,000	-43,210,000
Income Tax Expense	25,000	22,000	14,000	956,000
Net Income	-10,536,000	-17,759,000	-20,131,000	-44,166,000
Per Share
EPS	-1.04	-3.22	-13.02	-0.77
EPS Diluted	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Biofrontera AG (0DOL.L).
Balance Sheet (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	6,392,000	5,905,000	1,343,000	6,376,000
Short Term Investments	9,000	7,000	78,000	0
Net Receivables	7,291,000	5,315,000	5,162,000	2,069,999
Inventory	1,426,000	6,646,000	10,908,000	4,794,000
Total Current Assets	18,083,000	20,700,000	23,075,000	15,056,000
Property Plant Equipment	3,742,000	983,000	1,746,000	3,012,000
Goodwill and Intangibles	2,650,000	35,000	2,629,000	1,198,000
Total Assets	28,564,000	22,101,000	27,932,000	32,725,000
Liabilities
Account Payables	6,666,000	1,856,000	8,906,000	1,984,000
Short Term Debt	332,000	548,000	4,595,000	0
Total Current Liabilities	11,895,000	12,021,000	18,088,000	8,387,000
Long Term Debt	5,829,000	4,374,000	804,000	0
Total Liabilities	18,084,000	17,668,000	23,139,000	12,389,000
Shareholders Equity
Retained Earnings	-127,945,000	-117,409,000	-99,650,000	-180,789,000
Total Shareholders Equity	10,480,000	4,433,000	4,793,000	20,336,000

Balance sheet annual history for Biofrontera AG (0DOL.L).
Balance Sheet (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Cash and Cash Equivalents	6,392,000	5,905,000	1,343,000	6,376,000
Short Term Investments	9,000	7,000	78,000	0
Net Receivables	7,291,000	5,315,000	5,162,000	2,069,999
Inventory	1,426,000	6,646,000	10,908,000	4,794,000
Total Current Assets	18,083,000	20,700,000	23,075,000	15,056,000
Property Plant Equipment	3,742,000	983,000	1,746,000	3,012,000
Goodwill and Intangibles	2,650,000	35,000	2,629,000	1,198,000
Total Assets	28,564,000	22,101,000	27,932,000	32,725,000
Liabilities
Account Payables	6,666,000	1,856,000	8,906,000	1,984,000
Short Term Debt	332,000	548,000	4,595,000	0
Total Current Liabilities	11,895,000	12,021,000	18,088,000	8,387,000
Long Term Debt	5,829,000	4,374,000	804,000	0
Total Liabilities	18,084,000	17,668,000	23,139,000	12,389,000
Shareholders Equity
Retained Earnings	-127,945,000	-117,409,000	-99,650,000	-180,789,000
Total Shareholders Equity	10,480,000	4,433,000	4,793,000	20,336,000

Cash flow quarterly history for Biofrontera AG (0DOL.L).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-10,536,000	-17,759,000	-20,131,000	-44,166,000
Depreciation & Amortization	138,000	1,149,000	1,064,000	607,000
Stock Based Compensation	951,000	1,019,000	1,045,000	0
Change in Working Capital	-3,484,000	6,212,000	-4,394,000	-811,000
Operating Cash Flow	-13,361,000	-10,270,000	-24,895,000	-3,895,000
Investing Activities
Capital Expenditure	-2,000	-60,000	-5,000	-981,000
Investments	-2,000	-10,000	-5,000	-981,000
Investing Cash Flow	2,998,000	-3,000	619,000	-981,000
Financing Activities
Debt Repayment	10,850,000	-265,000	3,904,000	-2,484,000
Common Stock Issued/Repurchased	10,850,000	0	4,507,000	0
Dividends Paid	0	0	0	0
Financing Cash Flow	10,850,000	14,835,000	8,411,000	4,344,000
Summary
Free Cash Flow	-13,363,000	-10,330,000	-24,900,000	-4,876,000
Net Change in Cash	487,000	4,562,000	-15,865,000	-532,000

Cash flow annual history for Biofrontera AG (0DOL.L).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-10,536,000	-17,759,000	-20,131,000	-44,166,000
Depreciation & Amortization	138,000	1,149,000	1,064,000	607,000
Stock Based Compensation	951,000	1,019,000	1,045,000	0
Change in Working Capital	-3,484,000	6,212,000	-4,394,000	-811,000
Operating Cash Flow	-13,361,000	-10,270,000	-24,895,000	-3,895,000
Investing Activities
Capital Expenditure	-2,000	-60,000	-5,000	-981,000
Investments	-2,000	-10,000	-5,000	-981,000
Investing Cash Flow	2,998,000	-3,000	619,000	-981,000
Financing Activities
Debt Repayment	10,850,000	-265,000	3,904,000	-2,484,000
Common Stock Issued/Repurchased	10,850,000	0	4,507,000	0
Dividends Paid	0	0	0	0
Financing Cash Flow	10,850,000	14,835,000	8,411,000	4,344,000
Summary
Free Cash Flow	-13,363,000	-10,330,000	-24,900,000	-4,876,000
Net Change in Cash	487,000	4,562,000	-15,865,000	-532,000